Population Pharmacokinetics of Ipilimumab in Combination With Nivolumab in Patients With Advanced Solid Tumors

• Main Authors: Kinjal Sanghavi (Author), Jason Zhang (Author), Xiaochen Zhao (Author), Yan Feng (Author), Paul Statkevich (Author), Jennifer Sheng (Author), Amit Roy (Author), Heather E. Vezina (Author)
• Format: Book
• Published: Wiley, 2020-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Ipilimumab is a fully human monoclonal antibody approved for the treatment of melanoma as monotherapy and for the treatment of melanoma, renal cell carcinoma, and colorectal cancer in combination with nivolumab. Ipilimumab time‐varying clearance (CL) was assessed by a population pharmacokinetics (PP...